Table 1 Distribution of molecular subtypes, menopausal status, tumor size, malignancy grade, and sentinel node (SN) status for 1556 patients.

From: Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status

Molecular subtype

NormL

 

LumA

 

LumB

 

LumC

 

mApo

 

BasL

 

No. of patients (%)*

339 (22)

 

597 (38)

 

230 (15)

 

149 (10)

 

71 (5)

 

170 (11)

 

Menopause

            

Premenopause

87 (26)

 

117 (20)

 

69 (30)

 

42 (28)

 

12 (17)

 

68 (40)

 

Postmenopause

252 (74)

 

480 (80)

 

161 (70)

 

107 (72)

 

59 (83)

 

102 (60)

 

Tumor size

            

11–20 mm

232 (68)

 

381 (64)

 

120 (52)

 

94 (63)

 

39 (55)

 

94 (55)

 

 > 20 mm

107 (32)

 

216 (36)

 

110 (48)

 

55 (37)

 

32 (45)

 

76 (45)

 

Grade

            

1

159 (47)

 

210 (35)

 

15 (7)

 

20 (13)

 

2 (3)

 

0 (0)

 

2

168 (50)

 

323 (54)

 

113 (49)

 

71 (48)

 

16 (23)

 

14 (8)

 

3

6 (2)

 

38 (6)

 

99 (43)

 

54 (36)

 

46 (65)

 

144 (85)

 

N/A

6 (2)

 

26 (4)

 

3 (1)

 

4 (3)

 

7 (10)

 

12 (7)

 

SN status

            

SN-negative

232 (68)

 

370 (62)

 

143 (62)

 

92 (62)

 

49 (69)

 

134 (79)

 

SN-positive

107 (32)

 

227 (38)

 

87 (38)

 

57 (38)

 

22 (31)

 

36 (21)

 
 

SN-

SN + 

SN-

SN + 

SN-

SN + 

SN-

SN + 

SN-

SN + 

SN-

SN + 

No systemic treatment

13 (6)

4 (4)

21 (6)

5 (2)

6 (4)

1 (1)

2 (2)

4 (7)

6 (12)

1 (5)

15 (11)

2 (6)

ET only

167 (72)

52 (49)

258 (70)

134 (59)

59 (41)

21 (24)

37 (40)

20 (35)

4 (8)

4 (18)

4 (3)

0 (0)

ET + CT

43 (19)

44 (41)

65 (18)

74 (33)

69 (48)

60 (69)

44 (48)

27 (47)

6 (12)

9 (41)

23 (17)

12 (33)

CT only

2 (1)

3 (3)

4 (1)

3 (1)

3 (2)

2 (2)

3 (3)

4 (7)

25 (51)

7 (32)

79 (59)

20 (56)

No registration (N/A)

7 (3)

4 (4)

22 (6)

11 (5)

6 (4)

3 (3)

6 (7)

2 (4)

8 (16)

1 (5)

13 (10)

2 (6)

(%) col

            
  1. ET endocrine therapy, CT chemotherapy.